ARTKX
Price
$58.60
Change
-$0.37 (-0.63%)
Updated
Sep 18 closing price
Net Assets
45.96B
VTMNX
Price
$23.02
Change
-$0.23 (-0.99%)
Updated
Sep 18 closing price
Net Assets
323.82B
Interact to see
Advertisement

ARTKX vs VTMNX

ARTKX vs VTMNX Comparison Chart in %
View a ticker or compare two or three
VS
ARTKX vs. VTMNX commentary
Sep 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARTKX is a Buy and VTMNX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VTMNX has more cash in the bank: 324B vs. ARTKX (46B). VTMNX pays higher dividends than ARTKX: VTMNX (2.49) vs ARTKX (1.35). ARTKX was incepted earlier than VTMNX: ARTKX (24 years) vs VTMNX (26 years). ARTKX (1.20) is less costly to investors than VTMNX (0.03). ARTKX is a more actively managed with annual turnover of: 24.70 vs. VTMNX (4.00). ARTKX has a lower initial minimum investment than VTMNX: ARTKX (1000) vs VTMNX (5000000). VTMNX annual gain was more profitable for investors over the last year : 19.65 vs. ARTKX (9.41). VTMNX (41.15) and ARTKX (40.47) have equivalent 5 years return.
ARTKXVTMNXARTKX / VTMNX
Total Expense Ratio1.200.034,000%
Annual Report Gross Expense Ratio1.200.034,000%
Fund Existence24 years26 years-
Gain YTD10.06314.85368%
Front LoadN/AN/A-
Min. Initial Investment100050000000%
Min. Initial Investment IRAN/AN/A-
Net Assets46B324B14%
Annual Yield % from dividends1.352.4954%
Returns for 1 year9.4119.6548%
Returns for 3 years39.8160.9765%
Returns for 5 years40.4741.1598%
Returns for 10 years98.37105.9893%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TSRPX23.36N/A
N/A
Nuveen Quant Small Cap Equity Premier
VBINX54.40-0.05
-0.09%
Vanguard Balanced Index Inv
AWTAX18.51-0.07
-0.38%
Virtus Duff & Phelps Water A
FDTGX89.27-0.60
-0.67%
Fidelity Advisor Consumer Staples M
RYBOX77.00-0.91
-1.17%
Rydex Biotechnology A